According to a news source, Enanta Pharmaceuticals, Inc. and Tetraphase Pharmaceuticals, Inc. were poised to raise a combined total of $146 million in two initial public offerings (IPOs) this week. Watertown, Massachusetts-based Enanta focuses on research and development involving “novel inhibitors designed for use against the hepatitis C virus.” It has also apparently created antibiotics to treat multi-drug resistant bacteria. Tetraphase, also based in Watertown, describes itself as “a clinical-stage life science company developing a portfolio of potent new antibiotics to be effective against dangerous, drug-resistant bacteria.” Its most advanced product has apparently completed Phase II clinical testing. See Boston Business Journal, March 15, 2013.